Two Directors Step Down from Elan Board in Accordance with Previously Announced Intention

Two Directors Step Down from Elan Board in Accordance with Previously Announced Intention
Company Confirms It Expects To Name New Chairman By Year End
DUBLIN, Nov 01, 2010 (BUSINESS WIRE) --

Elan Corporation, plc ("Elan") (NYSE: ELN) said today that two of its directors, Jack Schuler and Vaughn Bryson, resigned from the Board effective October 29, 2010, in accordance with their previously announced intention and their related agreements with Elan.


Separately, Elan confirmed that, as previously announced, it expects to name a new Chairman of the Board by year end.

About Elan

Elan Corporation, plc (NYSE: ELN) is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the Company, please visit www.elan.com.

Source: Elan Corporation, plc

 

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.